Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.
I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.
The company’s pipeline includes several promising candidates:
- Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
- Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
- Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
- Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
- Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).
I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.
Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.
For the latest updates and detailed information, visit the official website at I-Mab Biopharma.
I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, has announced significant clinical advancements for its CD73 antibody, uliledlimab (TJD5), targeting advanced solid tumors. The company has initiated a phase 1/2 study in China and completed initial assessments in the U.S., demonstrating the safety and clinical activity of uliledlimab in combination with PD-1 inhibitors. Detailed results are expected at major conferences in 2021. I-Mab aims to offer innovative therapies for patients unresponsive to existing treatments.
I-Mab (NASDAQ: IMAB) announced the dosing of the first patient in a phase 2 clinical trial of TJ107 (efineptakin alpha), a long-acting recombinant human interleukin-7, for glioblastoma multiforme patients in China. The trial aims to evaluate the drug's efficacy in boosting lymphocyte counts post-chemoradiotherapy. Previous studies indicated TJ107's potential in improving immune function without severe toxicity. GBM remains a challenging cancer with poor outcomes, making innovative therapies like TJ107 critical for patients.
I-Mab (Nasdaq: IMAB) and MorphoSys (Nasdaq: MOR) have initiated a phase 1 dose escalation study for TJ210/MOR210 in the U.S., focusing on patients with relapsed or refractory advanced solid tumors. This monoclonal antibody targets the C5a receptor, aiming to disrupt tumor-promoting myeloid cells. Preclinical studies indicate safety and anti-tumor activity. The trial will inform the safety and tolerability of TJ210/MOR210, with future combination studies planned. MorphoSys will receive a $1.5 million milestone payment from I-Mab as part of their collaboration agreement.
I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in several upcoming conferences in January 2021. Key events include the H.C. Wainwright BioConnect 2021 Conference on January 11, and the Citi and UBS Greater China Healthcare Corporate Days on January 14-15 and January 18-22, respectively. Notable management participants include founder Dr. Jingwu Zang and CEO Dr. Joan Huaqiong Shen. I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases, striving to transition into a fully integrated global biopharmaceutical entity.
I-Mab (Nasdaq: IMAB) announced on December 14, 2020, that its American Depositary Shares (ADS) will be included in the NASDAQ Biotechnology Index, effective December 21, 2020. This inclusion marks a significant milestone, highlighting the company's progress since its IPO in January 2020. I-Mab aims to enhance its capital market profile and provide value to shareholders, with a pipeline focused on immuno-oncology and autoimmune diseases. The NBI tracks biotechnology and pharmaceutical securities, allowing investors to follow market trends.
I-Mab (Nasdaq: IMAB) announced the advancement of its clinical development for the anti-CD47 monoclonal antibody, lemzoparlimab, in the US and China, achieving key milestones. The US combination trial will evaluate lemzoparlimab with Rituxan® and Keytruda® in non-Hodgkin lymphoma and advanced tumors, with results expected next year. In China, a phase 1/2a trial and a new IND application for a combination trial with azacitidine in AML/MDS have been accepted. I-Mab's partnership with AbbVie will support global development, positioning the company for significant advancements in cancer therapy.
I-Mab (Nasdaq: IMAB) filed a registration statement on Form F-1 with the SEC for 25,123,751 ordinary shares, equivalent to 10,923,370 American depositary shares. These shares are beneficially owned by PIPE Investors under subscription agreements dated September 3, 2020. The preliminary prospectus is available on the SEC's website. This announcement does not constitute an offer to sell securities prior to registration.
I-Mab focuses on developing novel biologics in immuno-oncology and autoimmune diseases, aiming to transition into a fully integrated global biopharmaceutical company.
I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, has enhanced its Scientific Advisory Board with the appointments of Dr. Chen Dong and Dr. Jun Ma. Both experts bring extensive knowledge in immunology and hematology, respectively. Dr. Dong, a leading immunologist, is recognized for his contributions to T cell biology, while Dr. Ma specializes in treatments for leukemia and lymphoma. Their expertise aims to advance I-Mab's mission of developing transformational medicines for patients worldwide.
I-Mab (Nasdaq: IMAB) announces an investor call on November 13, 2020, at 8:20 a.m. ET, to discuss preliminary results from a Phase 1 clinical trial evaluating lemzoparlimab for relapsed or refractory solid tumors. This call aims to provide detailed analysis of clinical efficacy signals from the trial, recently presented at the 2020 Society for Immunotherapy of Cancer Annual Meeting. The Company is advancing further studies of lemzoparlimab in combination with other treatments like Keytruda and Rituxan.
I-Mab (Nasdaq: IMAB) announced new preclinical data for its C5aR antibody project, TJ210/MOR210, at the SITC Annual Meeting. The data will be presented on November 12, 2020. TJ210/MOR210, developed in collaboration with MorphoSys, is an anti-C5aR monoclonal antibody designed to inhibit tumor-promoting cells. Key findings show high affinity binding to C5aR1, significant tumor growth inhibition in combination with anti-PD-1 therapy, and a favorable safety profile in toxicity studies. The FDA recently approved an IND application to initiate a phase 1 trial for advanced solid tumors.
FAQ
What is the current stock price of I-MAB American Depositary Shares (IMAB)?
What is the market cap of I-MAB American Depositary Shares (IMAB)?
What is I-Mab's core focus?
What are some key products in I-Mab's pipeline?
Where are I-Mab's main operations located?
What recent strategic move has I-Mab made?
What is felzartamab?
Who is I-Mab collaborating with on givastomig?
How does I-Mab fund its operations and research?
What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?
What is I-Mab's approach to drug development?
How can investors stay updated on I-Mab's progress?
